For many compounds (neurotrophic factors, antibodies, growth factors, genetic vectors, enzymes) slow diffusion in the brain severely limits drug distribution and effect after direct drug admistration into brain parenchyma.
Limited penetration into the central nervous system (CNS) after systemic administration of most drugs has been known since Ehrlich first described the blood-brain barrier in 1885. This limitation is most pronounced with high molecular weight and polar molecules (1, 2) . Many new drugs with therapeutic potential are polar proteins with a high molecular weight (growth factors, enzymes, antibodies, protein conjugates, genetic vectors) (3) (4) (5) (6) . One strategy to circumvent the blood-brain barrier and to improve drug delivery to the CNS is direct administration into the cerebrospinal fluid (CSF) or the brain parenchyma. However, ventriculocisternal perfusion relies on diffusion for distribution into the brain parenchyma and poor penetration occurs, even with drugs with ideal characteristics for diffusion (7) . Penetration from CSF into brain is extremely limited for high molecular weight compounds (8) . After direct administration into the brain, limited diffusion in the brain severely retards the rate of distribution of such compounds.
Intratumoral chemotherapy for brain tumors has been administered by direct injection, intracavitary instillation, intracavitary topical application, chronic low-flow microinfusion, and controlled release from polymer implants (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) . Intracavitary delivery has also been used to deliver biological reagents, including interferons and interleukin 2, to tumors (4, 20, 21) . However, the efficacy of intratumoral drug administration is restricted by the poor diffusion of drug through tumor and brain interstitium relative to tissue clearance so that only a small volume of tissue surrounding the drug source is treated (18, 19, 22) . Thus, poor drug delivery to the CNS limits application of promising basic findings for further research and treatment of neurological diseases such as neurodegenerative disorders, CNS tumors, and inborn errors of metabolism.
Diffusion of a compound in a tissue depends solely on the free concentration gradient and the diffusivity of that compound in that tissue. It is very slow for high molecular weight compounds in tumor and normal tissues (3, 23, 24) . Diffusion of IgG in tumor requires 3 days to reach 1 mm from the point of origin (3) . Low molecular weight compounds, on the other hand, have a higher diffusivity in brain and tumor, but loss via capillaries and (for some) metabolism generally limits therapeutic drug levels to a few millimeters from the source of drug (19, 22, 25) .
Fluid convection, or bulk flow, in tissues occurs as a result of pressure gradients. Bulk flow of brain interstitial fluid occurs under normal conditions (26) , with vasogenic edema (27) , and after infusion of solutions directly into the brain parenchyma (28) (29) (30) . Furthermore, bulk flow of brain interstitial fluid alters the distribution of dextran blue dye (Mr, 2 x 106) injected intracerebrally (31) . We report that fluid convection within the brain, established by maintaining a pressure gradient during interstitial infusion, can be used to supplement diffusion and greatly enhance the distribution of small and large molecules, including high molecular weight proteins.
MATERIALS AND METHODS
Infuson Procedure. Artificial CSF containing l'lln-labeled transferrin (111In-Tf; Mr, 80,000) and ['4C]sucrose (Mr, 359) was infused for [1] [2] [3] [4] sure, blood pressure, and electrocardiogram were recorded on a Gould strip chart recorder (Gould, Cleveland). Infusion line pressure was monitored with a P 50 Stratham pressure transducer (Gould). Cisterna magna and blood pressure were monitored with a model 4-327-I pressure transducer (Bell & Howell, Pasadena, CA).
Infusions were performed with a model 22 Harvard syringe pump (Harvard Apparatus). Five-centimeter stainless steel 23-g blunt infusion cannulae were connected to 3-ml syringes (Sherwood-monoject, St. Louis) with 60 cm of PE-50 tubing (Clay Adams). After the cannulae were inserted, the line pressure was allowed to stabilize for 2-5 min. Infusions were started at 0.5 Al/min and continued at that rate until the pressure plateau in the infusion line (-30 min) and then the infusion rate was incrementally increased to 1, 2, 3, and finally 4 Al/min, pausing at each rate to allow the line pressure to plateau (-10 min). The rate of infusion was then kept at 4 A.l/min until the total volume was infused.
This work was performed in accordance with the NIH guidelines on the use of animals in research and was approved by the NINDS Animal Care and Use Committee and by the NIH Radiation Safety Committee. (1 Ci = 37 GBq) (Mediphysics, Arlington Heights, IL) and incubated at 370C for 1 h. The solution was then layered on a PD-10 column (Pharmacia) and eluted with phosphatebuffered saline (PBS) (pH 7.4) (Biofluids, Rockville, MD). Radioactivity in eluted fractions was detected with a y-counter (Pharmacia LKB). Recovery of In was >95% in pooled fractions containing In-Tf. The solution prepared for infusion contained 111In-Tf (0.3 mCi/ml; 0.86 mg/ml), [14C]sucrose (2 uCi/ml; 0.001 mg/ml; Sigma), and dextran blue (Mr, 2 x 106; 2.8 mg/ml; Sigma) in PBS (pH 7.4) (osmolarity, 314 mosM).
Analysis of "'1In-Tf and [14C]Sucrose Distribution in Brain
After Infusion. The effects of infusion volume (75, 300, or 600
Al per hemisphere), molecular weight, and redistribution over time (animals were sacrificed 0, 2, and 24 h after completion of infusion) on the volume of distribution (Vd) of the infused compounds were studied. The Vd, anatomic distribution, and concentration profiles in brain were determined by quantitative autoradiography and computerized image analysis (33, 34 Animals were killed 0, 2, and 24 h after completing an infusion; the brain was removed and cut into 8-mm-thick coronal sections, which were placed on coverslips and frozen on dry ice. Twenty-micrometer coronal brain sections were then cut on a cryostat (Microm, Heidelberg); six sections were obtained at 1-mm intervals through the brain (four for autoradiography, two for histology). Double-label quantitative autoradiography (QAR) was performed as described by Blasberg et al. (33) . QAR 111In standards were prepared from homogenized brain at concentrations of 0.01-0.8 relative to the infusion "'In concentration. QAR 14C standards were obtained from Amersham. "'In-Tf present in brain sections was allowed to decay >12 weeks (30 half-lives) before exposing the sections for 14C determination. Sections for histology were stained with Luxol fast blue-periodic acid/ Schiff stain and hematoxylin and eosin.
Image analysis was performed on a Macintosh IIfx computer (Apple Computers, Cupertino, CA) using the program IMAGE (NIH public domain software available on Internet). A high-resolution video camera (Sierra Scientific, Sunnyvale, CA) was used in combination with a precision illuminator (Northern Light, model 890) to digitize the autoradiograms. For each coronal section containing isotope, the area of distribution containing a minimum concentration of isotope (relative to concentration of infused solution) was determined for each minimum threshold concentration ranging from 0.01 to 0.8. Volumes of distribution were determined by summing areas of distribution over the volume of brain containing isotope, and differences were evaluated by analysis of variance.
Determination 18 min) of increasing pressure in the infusion line to reach a peak pressure of 57 ± 24 mmHg (mean ± SD; n = 12) (Fig. 1) . This was followed by a rapid decrease in infusion pressure to a pressure of 26 ± 9 mmHg. (The abrupt drop in line pressure near 13 min during the infusion illustrated in Fig. 1 (Fig. 2) .
The greater volumes associated with sucrose are consistent with diffusion occurring on the edges of the infused volume and a diffusional distance of 0.3-0.4 cm. Immediately after completion ofinfusion of600 p1, 50%o ofthe cat hemisphere had received .o1% of the concentration of '"1In-Tf in the infusion. Since diffusion of Tf over the 3 h of infusion is negligible, this distribution was the result of convection (3, 8, 23) . After infusion was complete, the Vd containing .1o% of the infusion concentration increased for Tf over 24 h and increased for sucrose for at least 2 h (Fig. 3 ). There was a significant decrease (P < 0.01) in the Vd, which contained >60% of the infusion concentration for both Tf and sucrose from 0 to 24 h after the infusion. Thus, the concentration profiles of sucrose and Tf were increasingly homogeneous over time after the infusion was completed. The increase in the Vd for sucrose and Tfover time includes increased delivery to gray matter. Sucrose distributed into gray matter more rapidly than Tf with penetration to the cortical surface apparent by 2 h after completing a white matter infusion (Fig. 3B) . Although it predominantly distributed in white matter immediately after infusion, Tf increasingly penetrated gray matter over the next 24 h (Fig. 4) molecular weight compounds, low diffusivity in brain, or in tumor, relative to tissue clearance limits distribution. For low molecular weight compounds, capillary loss and metabolism often underlie the restricted distribution. The short distribution distances and the steep concentration gradients associated with diffusion limit the utility of purely diffusive drug delivery for regional therapy of CNS disorders. Our results demonstrate that it should be feasible to exploit fluid convection to enhance drug transport through regions of brain or tumor.
Infusion rates are critical for successful induction of convection in brain. Rates of infusion greater than a few microliters per minute produce leakage of infusion solution out the cannula tract and loss of infusion pressure. Since the CNS can remove fluid from the interstitial space in edematous white matter at about 0.3-0.5 tildmin' ml-1 (35) , equivalent to -2.5 IL/min per hemisphere in the cat, much slower rates of infusion limit the attainable volume of distribution at a specific drug concentration. By incrementally increasing the infusion rates from 0.5 to 4.0 tA/min, we distributed Tf to an extent considerably exceeding that which would occur by diffusion alone. Two-hour infusions spread Tf -1. (38) , this penetration depth increases to 0.39 cm. For both chemical species, but especially for the macromolecule, diffusion thus exposes a significantly smaller volume of distribution than does high-flow microinfusion.
The infused macromolecule, Tf, is capable of binding to Tf receptors and being internalized by cells bearing those receptors. When active, such processes are capable ofaffecting both the magnitude and the timing of spread. However, these complications were avoided in the present experiments by infusion of Tf solutions at concentrations that were nearly 5 orders of magnitude in excess of reported tissue-averaged brain Tf-receptor densities of 0.04 nM (39) . Maximal rates of endocytosis have been measured in teratocarcinoma stem cells at one full receptor complement every 6 min (40). Applied to the brain receptor density, this translates into a maximal uptake rate of 0.007 nM/min. A 4-h infusion of our Tf solution would therefore lead to a concentration reduction of only 0.015% near the leading edge of the infusion profile.
All of the interstitial brain infusions performed in this study were well tolerated and were associated with no hemodynamic instability during the infusions. The two animals that were allowed to recover from anesthesia demonstrated transient lethargy and weakness that resolved by 24 In a variety of experimental models, cerebral edema does not cause neurologic dysfunction as long as intracranial pressure is not appreciably elevated (42, 43) . Furthermore, neurologic deficits associated with cerebral edema in patients with brain tumors are reversible after reduction of peritumoral edema with medical therapy, suggesting that even when edema is severe enough to cause neurologic dysfunction, deficits related to edema are reversible. Thus, evidence from experimental and clinical studies indicates that cerebral edemaper se does not alter brain function as long as there are no associated herniations of cerebral tissue, significant elevation ofintracranial pressure, or reduction of cerebral blood flow below the normal range (44) .
Convection can be used to supplement diffusion for distribution of certain compounds to treat much larger volumes of brain than can be achieved by diffusion alone and with a very great pharmacokinetic advantage over systemic administration. After systemic administration, macromolecules rarely reach concentrations in the CNS extracellular fluid of 1% of plasma concentration (2) . After interstitial infusion, brain concentrations ofTfand sucrose were >100-fold higher than systemic concentrations. The technique described here has the potential of overcoming some of the drug delivery problems imposed by limited drug diffusion through the brain interstitium when attempting to circumvent the blood-brain barrier by delivering drugs directly into brain parenchyma. This technique for drug delivery may also enhance drug distribution in tumors in the CNS and elsewhere.
